Search results for "Atrophy"

showing 10 items of 385 documents

Assessment of clinical outcomes and histomorphometric findings in alveolar ridge augmentation procedures with allogeneic bone block grafts: A systema…

2020

Background This systematic literature review aimed to evaluate the efficacy of allogeneic bone blocks for ridge augmentation by assessing block survival rates and subsequent implant survival, including post-surgical complications and histomorphometric analysis. Material and Methods An electronic and manual search among references, was conducted up to April 2019 by two independent authors. Inclusion criteria were: human clinical trials in which the outcomes of allogeneic bone block grafts were evaluated by means of their survival rates and subsequent implant success rates. Results Seven articles fulfilled the inclusion criteria and were analyzed. A total of 323 allogeneic block grafts were m…

medicine.medical_specialtymedicine.medical_treatmentReviewHematopoietic stem cell transplantation03 medical and health sciences0302 clinical medicineBlock (telecommunications)medicineHumansAutogenous boneGeneral DentistrySurvival rateDental ImplantsBone Transplantationbusiness.industryDental Implantation EndosseousHematopoietic Stem Cell TransplantationAlveolar Ridge Augmentation030206 dentistryAlveolar Ridge Augmentation:CIENCIAS MÉDICAS [UNESCO]SurgeryClinical trialOtorhinolaryngologyMeta-analysisUNESCO::CIENCIAS MÉDICASSurgeryImplantOral SurgeryAtrophybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Exposure to ototoxic agents and hearing loss: A review of current knowledge

2014

Several experimental and clinical studies have shown that a variety of ototoxic agents (such as drugs, industrial chemicals and noise) can cause sensorineural hearing loss. The most common ototoxic drugs used in clinical practice include: aminoglycoside and macrolide antibiotics, quinoline anti-malarials, platinum analog antineoplastics, loop diuretics, and acetylsalicylic acid. Among chemical agents with potential ototoxic properties are: organic solvents, heavy metals, organotins, nitriles, asphyxiants, and pesticides/herbicides. Acoustic exposure to high intensity and/or prolonged noise can also cause permanent threshold shifts in auditory perception. Ototoxic agents can influence audito…

medicine.medical_specialtypharmacological injuryEndolymphHearing lossototoxicity hearing loss pharmacological injury reactive oxygen speciesPharmacologyAudiologyProinflammatory cytokineSpeech and HearingAtrophyOtotoxicitymedicinehearing lossreactive oxygen specieschemistry.chemical_classificationReactive oxygen speciesbusiness.industrySettore MED/44 - Medicina Del LavoroAminoglycosidemedicine.diseaseototoxicity; hearing loss; pharmacological injury; reactive oxygen speciesSettore MED/32 - AudiologiaototoxicitySettore MED/31 - Otorinolaringoiatriamedicine.anatomical_structureOtorhinolaryngologychemistrySettore BIO/14 - FarmacologiaSensorineural hearing lossmedicine.symptombusinessHearing, Balance and Communication
researchProduct

Role of  1-Adrenoceptor Subtypes in Pupil Dilation Studied With Gene-Targeted Mice

2014

PURPOSE The α₁A-adrenoceptor (α₁A-AR) subtype was suggested to mediate contraction and trophic effects in the iris dilator muscle, and thus its pharmacological blockade may be involved in intraoperative floppy iris syndrome. We tested the hypothesis that the α₁A-AR mediates pupil dilation and trophic effects in the mouse iris. METHODS The α₁-AR subtype mRNA expression was quantified in iris tissue by real-time PCR. To assess the role of individual α₁-ARs for mediating pupil dilation, the α₁-AR agonist phenylephrine was topically applied to the ocular surface of mice deficient in one of the three α₁-AR subtypes (α₁A-AR(-/-), α₁B-AR(-/-), α₁D-AR(-/-), respectively) and wild-type controls. Cha…

medicine.medical_specialtyurogenital systemIntraoperative floppy iris syndromeAnatomyBiologymedicine.diseaseSensory SystemsPupilCellular and Molecular NeuroscienceOphthalmologyIris dilator muscleEndocrinologyAtrophyInternal medicinemedicinePupillary responseMydriasismedicine.symptomReceptorPhenylephrinemedicine.drugInvestigative Ophthalmology & Visual Science
researchProduct

Alveolar distraction osteogenesis for dental implant treatments of the vertical bone atrophy : a systematic review

2019

Background To determine if alveolar vertical distraction osteogenesis obtains better results compared to other bone regeneration treatments (guided bone regeneration with membranes and / or filling material, or autogenous bone graft) in terms of bone gain, complications, and implant survival and success rates. Material and Methods An electronic search was performed in Pubmed (MEDLINE), Cochrane Library and Scopus databases in March 2017. Besides, a manual search was carried out. Inclusion criteria were randomized controlled trials published within the last 10 years with at least 1 year of follow-up after implant placement. No language restriction was applied. Exclusion criteria were studies…

medicine.medical_treatmentAlveolar Bone LossOsteogenesis DistractionDentistryReviewMandibleCochrane LibraryBone resorptionlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawPathologyMedicineHumansDental implantBone regenerationGeneral DentistryRandomized Controlled Trials as TopicDental ImplantsCirurgiaImplants dentalsbusiness.industryDental implants030206 dentistryAlveolar Ridge AugmentationAlveolar Ridge Augmentation:CIENCIAS MÉDICAS [UNESCO]PatologiaOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASDistraction osteogenesisSurgeryImplantOral SurgeryAtrophybusiness
researchProduct

Predictability of short implants ( < 10 mm) as a treatment option for the rehabilitation of atrophic maxillae: a systematic review

2016

Background Short implants (< 10 mm) are one of the treatment options available in cases of limited vertical bone. A purpose of this paper is to evaluate the predictability of short implants as an alternative to technically molthough such implants are now widely used, there is controversy regarding their clinical reliability. There complex treatments in patients with atrophic maxillae, based on a systematic review of the literature and the analysis of the implant survival rates, changes in peri-implant bone level, and associated complications. It is postulated that short implants offer clinical results similar to those of longer implants. Material and Methods A Medline-PubMed search was made…

medicine.medical_treatmentMEDLINEDentistryOdontologíaReview03 medical and health sciences0302 clinical medicineMaxillaHumansMedicineDental Restoration Failure030212 general & internal medicineBone levelGeneral DentistryDental ImplantsImplantes dentalesRehabilitationbusiness.industryDental Implantation EndosseousDental prosthesisReproducibility of ResultsTreatment options030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludShort implantsOtorhinolaryngologyMaxillaUNESCO::CIENCIAS MÉDICASOdontología restauradoraSurgeryDental Prosthesis Implant-SupportedImplantOral SurgeryAtrophybusiness
researchProduct

Exercise medicine for cancer cachexia: targeted exercise to counteract mechanisms and treatment side effects.

2022

Abstract Purpose Cancer-induced muscle wasting (i.e., cancer cachexia, CC) is a common and devastating syndrome that results in the death of more than 1 in 5 patients. Although primarily a result of elevated inflammation, there are multiple mechanisms that complement and amplify one another. Research on the use of exercise to manage CC is still limited, while exercise for CC management has been recently discouraged. Moreover, there is a lack of understanding that exercise is not a single medicine, but mode, type, dosage, and timing (exercise prescription) have distinct health outcomes. The purpose of this review was to examine the effects of these modes and subtypes to identify the most opt…

muscle atrophyInflammationtumorCancer ResearchCachexiaexerciseDrug-Related Side Effects and Adverse Reactionslihaskatomuscle wastingGeneral MedicineMuscular AtrophylihasmassaOncologyinflammationNeoplasmsHumanssyöpätauditkakeksiavoimaharjoittelulihaskuntoMuscle SkeletalExercisecancer cachexiaJournal of cancer research and clinical oncology
researchProduct

Physiactisome: A New Nanovesicle Drug Containing Heat Shock Protein 60 for Treating Muscle Wasting and Cachexia.

2022

Currently, no commercially available drugs have the ability to reverse cachexia or counteract muscle wasting and the loss of lean mass. Here, we report the methodology used to develop Physiactisome&mdash;a conditioned medium released by heat shock protein 60 (Hsp60)&mdash;overexpressing C2C12 cell lines enriched with small and large extracellular vesicles. We also present evidence supporting its use in the treatment of cachexia. Briefly, we obtain a nanovesicle-based secretion by genetically modifying C2C12 cell lines with an Hsp60-overexpressing plasmid. The secretion is used to treat na&iuml;ve C2C12 cell lines. Physiactisome activates the expression of PGC-1&alpha; isoform 1, which is di…

muscle atrophyProteomicsCachexiaexerciseArticle ; cachexia ; muscle atrophy ; exercise ; exosome ; muscle wasting ; sarcopeniamuscle wastingGeneral MedicineChaperonin 60ddc:sarcopeniaMuscular Atrophycachexia; muscle atrophy; exercise; exosome; muscle wasting; sarcopeniaQuality of LifeexosomeHumanscachexia; exercise; exosome; muscle atrophy; muscle wasting; sarcopeniaMuscle SkeletalCells
researchProduct

miR-7 Restores Phenotypes in Myotonic Dystrophy Muscle Cells by Repressing Hyperactivated Autophagy

2019

International audience; Unstable CTG expansions in the 3' UTR of the DMPK gene are responsible for myotonic dystrophy type 1 (DM1) condition. Muscle dysfunction is one of the main contributors to DM1 mortality and morbidity. Pathways by which mutant DMPK trigger muscle defects, however, are not fully understood. We previously reported that miR-7 was downregulated in a DM1 Drosophila model and in biopsies from patients. Here, using DM1 and normal muscle cells, we investigated whether miR-7 contributes to the muscle phenotype by studying the consequences of replenishing or blocking miR-7, respectively. Restoration of miR-7 with agomiR-7 was sufficient to rescue DM1 myoblast fusion defects and…

musculoskeletal diseases0301 basic medicineoligonucleotidemuscle atrophyautophagyBiologyMyotonic dystrophyArticleMuscleblind03 medical and health scienceschemistry.chemical_compoundMyoblast fusion0302 clinical medicineDrug DiscoverymicroRNAmedicineMBNL1MyocyteMyotonic DystrophymiRNAtherapy[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyAutophagyUPS systemmiR-7medicine.diseasePhenotypeMuscle atrophyCell biology030104 developmental biologychemistry030220 oncology & carcinogenesisMolecular MedicineCTG expansionsmedicine.symptom[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Phenotypic spectrum and genomics of undiagnosed arthrogryposis multiplex congenital

2022

BackgroundArthrogryposis multiplex congenita (AMC) is characterised by congenital joint contractures in two or more body areas. AMC exhibits wide phenotypic and genetic heterogeneity. Our goals were to improve the genetic diagnosis rates of AMC, to evaluate the added value of whole exome sequencing (WES) compared with targeted exome sequencing (TES) and to identify new genes in 315 unrelated undiagnosed AMC families.MethodsSeveral genomic approaches were used including genetic mapping of disease loci in multiplex or consanguineous families, TES then WES. Sanger sequencing was performed to identify or validate variants.ResultsWe achieved disease gene identification in 52.7% of AMC index pati…

musculoskeletal diseasesArtrogriposi múltiple congènitaSettore BIO/18 - GENETICAhuman geneticsneuromuscular diseasesGenomicsBiologyCONTRACTURESCLASSIFICATIONdiseasessymbols.namesakeDiagnòsticGene mappingarthrogryposis multiplex congenitaExome SequencingOF-FUNCTION MUTATIONSGeneticsMedicine and Health SciencesgenomicsHumansGenetics (clinical)Exome sequencingArthrogryposisSanger sequencingGeneticsArthrogryposis multiplex congenitaGenetic heterogeneitySPINAL MUSCULAR-ATROPHYProteinsnervous system malformationsDYSTROPHYDisease gene identificationGENEHuman geneticsPedigreeETIOLOGYPhenotypesymbolsneuromuscularGenèticaTranscription Factors
researchProduct

Treatment of sarcopenia by targeting Akt and muscle specific ubiquitin ligases. Evidence from mice and from a clinical trial

2017

Disuse muscle wasting may take place as a result of several such as joint immobilization, inactivity or bed rest. There are no good therapies to treat it. Allopurinol, a drug commonly used to treat hyperuricemia and gout, protects muscle damage, specially after exhaustive exercise and results in functional gains in old persons. Thus, we tested its effect in the prevention of atrophy of the soleus muscle after two weeks of hindlimb unloading in experimental animals (mice), and lower leg immobilization following ankle sprain in humans (Registration of the clinical Trial: EUDRACT2011-003541-17). We have found show that allopurinol protects against muscle atrophy in both mice and humans. The pr…

musculoskeletal diseasesSoleus musclemedicine.medical_specialtybusiness.industrymedicine.medical_treatmentAllopurinolPharmacologymedicine.diseaseBed restBiochemistryMuscle atrophySurgeryGoutAtrophyPhysiology (medical)Sarcopeniamedicinemedicine.symptombusinessWastingmedicine.drugFree Radical Biology and Medicine
researchProduct